[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR930019637A - 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 - Google Patents

비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR930019637A
KR930019637A KR1019930003270A KR930003270A KR930019637A KR 930019637 A KR930019637 A KR 930019637A KR 1019930003270 A KR1019930003270 A KR 1019930003270A KR 930003270 A KR930003270 A KR 930003270A KR 930019637 A KR930019637 A KR 930019637A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
hydrogen
formula
general formula
Prior art date
Application number
KR1019930003270A
Other languages
English (en)
Inventor
하이트슈 홀거
헨닝 라이너
바그너 아달베르트
게르하르트 헤르만
벡커 라인하르트
쇨켄스 베른바르트
Original Assignee
귀틀라인, 슈미트
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 귀틀라인, 슈미트, 훽스트 아크티엔게젤샤프트 filed Critical 귀틀라인, 슈미트
Publication of KR930019637A publication Critical patent/KR930019637A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

본 발명은 안지오텐신 Ⅱ수용체의 고활성 길항제인 하기 일반식(Ⅰ)의 화합물에 관한 것이다.
상기식에서,은, 예를 들면 에틸이고,는 예를 들면 메틸이며, n은 예를 들면 O이고,은 예를 들면 COOH이며,는 예를 들면

Description

비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조 방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식(Ⅰ)의 화합물 및 생리학적으로 허용되는 이의 염.
  3. 상기식에서, a)은알킬이고, b)는는 1.알킬, 2.사이클로알킬, 3. 페닐 또는 4. 벤질이며, c)은 1. 수소, 2., 3,또는 4.이고, d)는 1., 2., 3., 4., 5., 6.또는 7.이며, e)는 1. 수소 또는 2.알킬이고, f)은 1. 수소 또는 2.이며, g)및는 동일하거나 상이하고, 1. 수소, 2.알킬, 3.사이클로알킬, 4.사이클로알킬-알킬, 5.아릴, 바람직하게는 페닐, 6.아릴-알킬, 7. 부분적으로 또는 완전히 수소화될 수 있는헤테로아릴, 8. 헤테로아릴 잔기가 부분적으로 또는 완전히 수소화 될 수 있는헤테로아릴-알킬, 9. 할로겐, 하이드록실,알킬, 메톡시, 니트로 및 시아노를 포함하는 시리즈 중에서 하나 또는 두개의 동일하거나 라디칼에 의해 차횐된 상기 5., 6., 7. 및 8. 에서 정의한 라디칼, 10.알케닐 또는알케노일, 11.사이클로알케닐, 12.사이클로알케닐-알킬. 13.아릴-알케닐, 14.헤티르아릴-알케닐 및 15.알키닐이며, h)은 수소이고, i) n은 0,1 또는 2이다.
  4. 제1항에 있어서,이 에틸 또는 n-프로필인 일반식(Ⅰ)의 화합물 또는 생물학적으로 허용되는 이의 염.
  5. 제1항에 있어서,이 n-프로필인 일반식(Ⅰ)의 화합물 또는 생리학적으로허용되는 이의 염.
  6. 제1항 내지 제3항 중의 어느 한 항에 있어서,가알킬이고이이며 n이 O이고가,또는이며이 수소 또는이고이 수소 또는알킬인 일반식(Ⅰ)의 화합물 및 생리학적으로 허용되는 이의 염.
  7. 일반식(Ⅱ)의 화합물을 일반식(Ⅲ)의 화합물을 알킬화하고, 일시적으로 도입된 보호 그룹을 다시 임의로 제거한 다음, 수득된 일반식 (Ⅰ)의 우레탄으로 임의로 전환시키고, 수득된 일반식 (Ⅰ)의 설폰아미드 또는 수득된 일반식(Ⅰ)의 우레탄을 일반식(Ⅰ)의 설포닐우레아로 임의로 전환시킨 다음 수득된 일반식(Ⅰ)의 화합물을 생리학적으로 허용되는 이의 염으로 전환시킴을 포함하여, 제1항에 청구된 일반식(Ⅰ)의 화합물 및 생리학적으로 허용되고 이의 염을 제조하는 방법.
  9. 상기식에서,및 n은 제1항에서 정의한 바와 같고, U는 이탈 그룹이다.
  10. 제1항 내지 제4항 중 어느 한 항에 있어서, 약제로 사용하기 위한 화합물.
  11. 제1항 내지 제4항 중 어느 한 항에 있어서, 고혈압 치료용 약제로 사용하기 위한 화합물.
  12. 제1항 내지 제4항 중의 어느 한 항에 청구된 화합물을 포함하는 약제학적 제제
  13. 제1항에 청구된 일반식(Ⅰ)의 화합물을 생리학적으로 허용되는 부형제 및, 경우에 따라 기타 첨가제 또는 보조제와 함께 적합한 투여 형태로 만드는 것을 포함하여, 제8항에 청구된 조성물을 제조하는 방법.
  14. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930003270A 1992-03-07 1993-03-05 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도 KR930019637A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07
DEP4207241.7 1992-03-07

Publications (1)

Publication Number Publication Date
KR930019637A true KR930019637A (ko) 1993-10-18

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930003270A KR930019637A (ko) 1992-03-07 1993-03-05 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도

Country Status (25)

Country Link
US (1) US5604251A (ko)
EP (1) EP0560177B1 (ko)
JP (1) JP3542813B2 (ko)
KR (1) KR930019637A (ko)
CN (1) CN1036341C (ko)
AT (1) ATE230732T1 (ko)
AU (1) AU663565B2 (ko)
BR (1) BR9300761A (ko)
CA (1) CA2091135A1 (ko)
CZ (1) CZ281983B6 (ko)
DE (1) DE59310323D1 (ko)
DK (1) DK0560177T3 (ko)
ES (1) ES2187501T3 (ko)
FI (1) FI930970A (ko)
HU (1) HUT64041A (ko)
IL (1) IL104971A0 (ko)
MA (1) MA22814A1 (ko)
NO (1) NO303632B1 (ko)
NZ (1) NZ247059A (ko)
PH (1) PH31466A (ko)
PL (1) PL173023B1 (ko)
RU (1) RU2116300C1 (ko)
SK (1) SK381192A3 (ko)
TW (1) TW215434B (ko)
ZA (1) ZA931585B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NO304429B1 (no) * 1992-12-17 1998-12-14 Sankyo Co Bifenylderivater, farmas°ytisk preparat og deres anvendelse for fremstilling av et medikament for behandling av hypertensjon og hjertesykdom
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
AU729793B2 (en) * 1996-12-13 2001-02-08 Zymogenetics Inc. Compositions and methods for stimulating bone growth
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
MXPA01009362A (es) 1999-03-19 2002-06-04 Squibb Bristol Myers Co Metodos para la preparacion de bifenil isoxazol sulfonamidas.
WO2004002226A1 (en) * 2002-06-28 2004-01-08 Baylor College Of Medicine Modulators of cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004112763A2 (en) * 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2005042487A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CA2544763A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
AU2004299058A1 (en) * 2003-12-12 2005-06-30 Aventis Pharmaceutical, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1737448A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2007014033A2 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of Colorado, A Body Corporate Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
CA2634437A1 (en) * 2005-12-20 2007-07-05 Gilead Colorado, Inc. 4,7-dihydrothieno¬2,3-b|pyridine compounds and pharmaceutical compositions
CN101522222B (zh) 2006-08-01 2012-04-18 得克萨斯系统大学董事会 激活β-肌球蛋白重链表达的微RNA的鉴定
DK2182969T3 (en) 2007-07-31 2017-02-27 Univ Texas Micro-RNA family that modulates fibrosis and its applications
EP2265291B1 (en) 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
AU2496492A (en) * 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
NO304429B1 (no) * 1992-12-17 1998-12-14 Sankyo Co Bifenylderivater, farmas°ytisk preparat og deres anvendelse for fremstilling av et medikament for behandling av hypertensjon og hjertesykdom

Also Published As

Publication number Publication date
NZ247059A (en) 1995-03-28
BR9300761A (pt) 1993-09-14
AU3401193A (en) 1993-09-09
CN1036341C (zh) 1997-11-05
NO930817L (no) 1993-09-08
CZ381192A3 (en) 1993-12-15
MA22814A1 (fr) 1993-10-01
HUT64041A (en) 1993-11-29
NO930817D0 (no) 1993-03-05
ES2187501T3 (es) 2003-06-16
SK279109B6 (sk) 1998-06-03
ATE230732T1 (de) 2003-01-15
EP0560177B1 (de) 2003-01-08
DE59310323D1 (de) 2003-02-13
RU2116300C1 (ru) 1998-07-27
CZ281983B6 (cs) 1997-04-16
EP0560177A1 (de) 1993-09-15
PL173023B1 (pl) 1998-01-30
TW215434B (ko) 1993-11-01
DK0560177T3 (da) 2003-04-14
PH31466A (en) 1998-11-03
FI930970A0 (fi) 1993-03-04
JP3542813B2 (ja) 2004-07-14
US5604251A (en) 1997-02-18
HU9300618D0 (en) 1993-05-28
JPH069572A (ja) 1994-01-18
FI930970A (fi) 1993-09-08
NO303632B1 (no) 1998-08-10
CA2091135A1 (en) 1993-09-08
SK381192A3 (en) 1998-06-03
CN1076192A (zh) 1993-09-15
AU663565B2 (en) 1995-10-12
IL104971A0 (en) 1993-07-08
PL297955A1 (en) 1993-09-20
ZA931585B (en) 1993-09-27

Similar Documents

Publication Publication Date Title
KR930019637A (ko) 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도
RU2337909C2 (ru) Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
ES2173074T3 (es) Derivados de xantina, procedimiento para su preparacion y su uso farmaceutico.
KR890008155A (ko) 신규인 유도체, 그 제조방법 및 의약에서의 사용
BR9408343A (pt) Derivados 5-(2-imidazolinil amino) benzimidazol sua preparação e seu uso como agonistas alfa-2 adrenoceptor
MX9200026A (es) Derivados de azol, procedimientos para su preparacion y su utilizacion.
DE69011318D1 (de) Diazinderivate als Angiotensin II Rezeptor Antagonisten.
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
ES514267A0 (es) "un procedimiento para la preparacion de derivados de pirrolidina".
KR900006296A (ko) 이미다졸린 유도체 및 그의 제조방법
ATE89547T1 (de) Dopamin-vorlaeufer.
ES2051479T3 (es) Uso de imidazoles substituidos en 4 para disminuir la presion intraocular.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
KR870007160A (ko) 신규의 디하이드로벤조푸란-및 크로만-카복스아미드 유도체, 그것의 제조 방법 및 신경이완제로서의 사용법
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
DE69330601D1 (de) Serotoninergische ergolin derivate
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
DE69015787D1 (de) Thiophenderivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
KR930021638A (ko) 이미다조피리딘
AU580079B2 (en) Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension
KR910021364A (ko) 신규 프로판아민, 그의 약리학적 특성 및 치료 목적, 특히 지사제로서의 용도
MX9206930A (es) Nuevos compuestos

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application